Biocompatibles Inc.'s recent $36m settlement with the federal government stemmed from allegations that the BTG Plc. subsidiary sold its LC Bead device as a combination product without proper approval, according to US Department of Justice. The arrangement included a guilty plea to a misdemeanor misbranding charge.
LC Bead is used to treat liver cancer, among other conditions. US FDA cleared it as an embolization device that could be placed in blood vessels to block or reduce...